Summit Therapeutics Inc
SMMTHealthcare|Biotechnology|USA
$15.25
-0.23 (-1.49%)
Tangible Book
$0.70
Earnings Power
$1.03
Clinical Trials (56)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06429436 Vending Machine Naloxone Distribution for Your Community (VENDY) | Harm Reduction, Naloxone | P4 | Active | 4,000 | Open-label | — |
| NCT05899608 Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Non-Small Cell Lung Cancer | P3 | Recruiting | 1,600 | RCT, Double-blind | Ivonescimab Injection, Pembrolizumab Injection |
| NCT07228832 Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer (CRC) | P3 | Recruiting | 600 | RCT, Double-blind | Drug: Ivonescimab Injection, Drug: Bevacizumab Injection |
| NCT07264075 Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | P3 | Recruiting | 780 | RCT, Open-label | Ivonescimab 10 mg/kg, Ligufalimab, Pembrolizumab (KEYTRUDA ®) |
| NCT06396065 Phase III Study of AK112 for NSCLC Patients | Non-Squamous Non-small Cell Lung Cancer | P3 | Active | 420 | RCT, Double-blind | AK112 Injection, Placebo Injection |
| NCT06767514 Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Non-Small Cell Lung Cancer | P3 | Recruiting | 780 | RCT, Double-blind | Ivonescimab Injection, Pembrolizumab Injection |
| NCT07397338 Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Advanced Solid Tumors, Metastatic Solid Tumors | P1P2 | Recruiting | 370 | Open-label | Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only) |
| NCT06567314 Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | P2 | Recruiting | 24 | Open-label | Ivonescimab |
| NCT07535437 A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P1P2 | Recruiting | 66 | Open-label | Ivonescimab, Dato-DXd, Osimertinib |
| NCT07070466 Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | Stomach Cancer Stage IV, Esophagus Cancer | P2 | Recruiting | 40 | Open-label | Ivonescimab, 5-Fluorouracil, Oxaliplatin, Leucovorin |
| NCT06940518 Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma | Ivonescimab, Clear Cell Renal Carcinoma | P2 | Recruiting | 40 | Open-label | Ivonescimab |
| NCT06980077 Ivonescimab for the Treatment of Thymic Cancer | Thymus Carcinoma | P2 | Recruiting | 25 | Open-label | Ivonescimab |
| NCT06959550 Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Recruiting | 90 | Open-label | Ivonescimab |
| NCT07094685 Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer | Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | P2 | Recruiting | 28 | Open-label | Ivonescimab |
| NCT06805617 A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers | Salivary Gland Cancer, Advanced Salivary Gland Carcinoma | P2 | Recruiting | 35 | Open-label | Ivonescimab |
| NCT06840834 Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy | Pleural Mesotheliomas | P2 | Recruiting | 38 | Open-label | Ivonescimab |
| NCT07214415 Veterans' Cognitive Function, Mental Health, and Quality of Life After Hyperbaric Oxygen Therapy | TBI Traumatic Brain Injury, PTSD - Post Traumatic Stress Disorder | P2 | Recruiting | 54 | Open-label | Hyperbaric Oxygen Therapy |
| NCT07057791 Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer | Extensive Stage Lung Small Cell Cancer | P2 | Recruiting | 60 | RCT, Open-label | Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg |
| NCT06672575 A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | Glioblastoma | P1P2 | Recruiting | 45 | Open-label | Ivonescimab |
| NCT06846346 Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma | P2 | Recruiting | 88 | Open-label | Ivonescimab, FOLFOX regimen, Irinotecan, Paclitaxel |
| NCT07017673 Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | TNBC, TNBC - Triple-Negative Breast Cancer | P2 | Recruiting | 34 | Open-label | Ivonescimab, Carboplatin, Docetaxel |
| NCT05382442 A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Active | 254 | RCT, Open-label | AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil |
| NCT07516925 A Study of Ivonescimab in People With Leiomyosarcoma | Leiomyosarcoma | P2 | Recruiting | 20 | Open-label | Ivonescimab |
| NCT06925724 A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Endometrial Cancer, Cervical Cancer | P2 | Recruiting | 50 | Open-label | Ivonescimab |
| NCT06529718 Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients | Biliary Tract Cancer | P2 | Recruiting | 72 | RCT, Open-label | Ivonescimab, FOLFOX regimen |
| NCT07535463 A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P1P2 | Recruiting | 53 | Open-label | Ivonescimab |
| NCT07619339 A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P1 | Recruiting | 16 | Open-label | Tepotinib, Ivonescimab |
| NCT07555093 A Study of Multiple Micronutrient Supplementation (MMS) to Increase Adherence With Digital Technology | Pregnancy, Adherence | N/A | Recruiting | 10,012 | RCT, Open-label | — |
| NCT06719492 Nutrition Education in Spine Surgery | Nutrition Education, Enhanced Recovery After Surgery | N/A | Active | 98 | RCT, Open-label | — |
| NCT07607301 Evaluation of the Effectiveness of the Genomics & Science DOJO 3.0 Learning Method in Improving Research Skills and Scientific Writing Among Researchers in Indonesia | Workshop, Critical Thinking Skill | N/A | Recruiting | 96 | RCT, Double-blind | — |
| NCT07225933 A Retrospective, Multi-center Real-world Study of Steerable Ureteroscopic Renal Evacuation (SURE) Procedure With the CVAC® System | Urolithiasis, Kidney Stone | Active | 3,000 | — | — | |
| NCT01759277 Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthroplasty | Postoperative Pain Following Knee Arthroplasty | P4 | Completed | 80 | RCT, Open-label | Control: Femoral perineural local anesthetic infusion, Experimental: Adductor Canal perineural local anesthetic infusion |
| NCT04802837 Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects | Clostridioides Difficile Infection | P3 | Terminated | 2 | RCT, Double-blind | Ridinilazole, Vancomycin |
| NCT00658034 Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue | Fatigue | P3 | Unknown | 20 | RCT, Single-blind | — |
| NCT03595553 Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection | Clostridioides Difficile Infection | P3 | Completed | 759 | RCT, Double-blind | Ridinilazole, Vancomycin |
| NCT07234877 Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | Non Small Cell Lung Cancer | P2 | Not Yet Recruiting | 158 | RCT, Open-label | Ivonescimab, Carboplatin, Pemetrexed, Paclitaxel, Paclitaxel-albumin |
| NCT04910100 Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension | Open-Angle Glaucoma, Ocular Hypertension | P2 | Completed | 226 | RCT, Double-blind | Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Solution 0.5 Percent |
| NCT02784002 A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) | Clostridium Difficile Infection | P2 | Completed | 27 | RCT, Open-label | Ridinilazole, Fidaxomicin |
| NCT02858362 Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | P2 | Terminated | 43 | Open-label | Ezutromid |
| NCT02092935 A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) | Clostridium Difficile Infection | P2 | Completed | 100 | RCT, Double-blind | SMT19969, Vancomycin |
| NCT07359456 Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases | Metastatic Colorectal Cancer | P2 | Not Yet Recruiting | 130 | RCT, Open-label | Ivonescimab, Bevacizumab, FOLFIRI Protocol |
| NCT07405190 Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC) | P2 | Not Yet Recruiting | 46 | Open-label | Ivonescimab, carboplatin, pemetrexed |
| NCT02056808 A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | P1 | Completed | 12 | Open-label | SMT C1100 |
| NCT02383511 Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet | Muscular Dystrophy, Duchenne | P1 | Completed | 12 | RCT, Double-blind | SMT C1100, SMT C1100, SMT C1100 |
| NCT03185169 GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors | Genitourinary Abnormality, Breast Cancer Female | Early P1 | Terminated | 14 | Open-label | — |
| NCT07126041 Scalable Public Health Empowerment, Research, and Education Sites (SPHERES) | Pregnancy, Neonatal Mortality | N/A | Not Yet Recruiting | 1,750,000 | RCT, Open-label | — |
| NCT01165437 Validation of a Novel Oscillometric-Based Algorithm for Determination of the Ankle-Brachial Index | Peripheral Arterial Disease | Completed | 161 | — | — | |
| NCT00208039 Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates | Respiratory Distress Syndrome, Bronchopulmonary Dysplasia | N/A | Completed | 89 | Open-label | Infasurf |
| NCT04944095 Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations | Covid-19, Subjects Vaccinated Against Covid-19 | Unknown | 10,000 | — | — | |
| NCT04761042 Wilderness Program for Adolescent and Young Adult Cancer Survivors | Cancer | N/A | Unknown | 40 | RCT, Single-blind | — |
| NCT06064162 Ketamine for MS Fatigue | Multiple Sclerosis | Early P1 | Completed | 21 | RCT, Open-label | ketamine |
| NCT00452309 Validation of a Correction Factor for Measurement of an Accurate Ankle-Brachial Index in the Seated Position | Peripheral Arterial Disease | Completed | 50 | — | — | |
| NCT00536185 Heart & Health Study | Heart Disease | N/A | Completed | 166 | RCT, Double-blind | — |
| NCT04292301 MRI Assessing Clinical Usability of STrategically Acquired Gradient Echo on Human Participants | MRI | N/A | Completed | 92 | Open-label | — |
| NCT00819598 Pilot Study to Determine the Optimal Technique for Measurement of Ankle Blood Pressures | Peripheral Arterial Disease | Completed | 70 | — | — | |
| NCT00667264 Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain | Amputation, Phantom Limb | N/A | Completed | 7 | RCT, Double-blind | — |